Norge -
norsk -
Statens legemiddelverk
anastrozol medical valley 1 mg
medical valley invest ab - anastrozol - tablett, filmdrasjert - 1 mg
Norge -
norsk -
Statens legemiddelverk
arimidex 1 mg
laboratoires juvisé pharmaceuticals - anastrozol - tablett, filmdrasjert - 1 mg
Norge -
norsk -
Statens legemiddelverk
anastrozole teva 1 mg
teva sweden ab - anastrozol - tablett, filmdrasjert - 1 mg
Norge -
norsk -
Statens legemiddelverk
arimidex 1 mg
orifarm as - anastrozol - tablett, filmdrasjert - 1 mg
Norge -
norsk -
Statens legemiddelverk
arimidex 1 mg
orifarm as - anastrozol - tablett, filmdrasjert - 1 mg
Norge -
norsk -
Statens legemiddelverk
arimidex 1 mg
orifarm as - anastrozol - tablett, filmdrasjert - 1 mg
Norge -
norsk -
Statens legemiddelverk
arimidex 1 mg
orifarm as - anastrozol - tablett, filmdrasjert - 1 mg
Norge -
norsk -
Statens legemiddelverk
arimidex 1 mg
orifarm as - anastrozol - tablett, filmdrasjert - 1 mg
Norge -
norsk -
Statens legemiddelverk
fulvestrant ever pharma 250 mg
ever valinject gmbh - fulvestrant - injeksjonsvæske, oppløsning i ferdigfylt sprøyte - 250 mg
Den europeiske union -
norsk -
EMA (European Medicines Agency)
faslodex
astrazeneca ab - fulvestrant - bryst neoplasms - endokrin terapi, anti-østrogener - faslodex is indicated , as monotherapy for the treatment of estrogen receptor positive, locally advanced or metastatic breast cancer in postmenopausal women:, , not previously treated with endocrine therapy, or, with disease relapse on or after adjuvant antiestrogen therapy, or disease progression on antiestrogen therapy. , , , in combination with palbociclib for the treatment of hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative locally advanced or metastatic breast cancer in women who have received prior endocrine therapy. i pre - eller perimenopausal women, kombinert behandling med palbociclib bør kombineres med en luteiniserende hormon-frigjørende hormon (lhrh) agonist.